[The influence of nebivolol on thrombocyte aggregation in patients with arterial hypertension with metabolic sydrome].
The research was undertaken with the purpose to assess the efficiency of nebivolol for correction of thrombocyte aggregation capability in patients having arterial hypertension (AH) with metabolic syndrome (MS). 21 patients were administered nebivolol in a dose of 5 mg per day for a month. The dynamic changes in the following parameters were evaluated: anthropometric measurements, blood lipid spectrum, lipid peroxidation in serum and thrombocytes, antioxidative protectability of the liquid part of blood and platelets, thrombocyte aggregation activity. The results were processed using Student criterion and system multifactoral analysis. Nebivolol reduced peroxidation syndrome and optimized thrombocyte aggregation in patients with AH and MS. When administered for a long period of time, nebivolol is able to stabilize the achieved effect. Combining nebivolol application with use of non-drug means is necessary to reduce body weight in patients having AH with MS.